Iron Deficiency Injectable Market 2024 Report By Key Companies, Regional Analysis And Forecast 2033

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Iron Deficiency Injectable Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $20.68 billion In 2028 At A CAGR Of 10.1% :

The iron deficiency injectable market size has grown rapidly in recent years. It will grow from $12.75 billion in 2023 to $14.06 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to high prevalence of iron deficiency anemia treatments, bariatric surgery patients, pediatric and adolescent patients, growing pregnancy.

The iron deficiency injectable market size is expected to see rapid growth in the next few years. It will grow to $20.68 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to geriatric population, global health initiatives, government initiatives, incresing treatments for chronic conditions, rapid iron replenishment. Major trends in the forecast period include advances in iron formulations, digital health solutions, advancements in iron deficiency injectable therapy, adoption of iron-based drugs,.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=12907&type=smp

Iron Deficiency Injectable Market Major Segments
The iron deficiency injectable market covered in this report is segmented -

1) By Type: Iron Dextran; Iron Sucrose; Ferric Carboxymaltose
2) By Branded or Generics: Branded; Generics
3) By Application: Chronic Kidney Disease; Inflammatory Bowel Disease; Cancer; Other Applications
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

Key Driver - Rising Prevalence Of Pcos Fuels Demand For Iron Deficiency Injectables

The increasing prevalence of polycystic ovar*y syndrome (PCOS) is expected to propel the growth of the iron deficiency injectables market going forward. Polycystic ovar*y syndrome (PCOS) is a common hormonal disorder that affects people with ovaries, primarily women of reproductive age. Polycystic ovar*y syndrome (PCOS) leads to iron overload, which results in excessive blood loss during menstruatio*n and makes patients anemic, which can be cured by injectable iron deficiency medications. For instance, in June 2023, according to the World Health Organization, a US-based specialized health agency, globally, polycystic ovar*y syndrome (PCOS) affects an estimated 8-13% of reproductive-aged women, among whom 70% remain undiagnosed. Therefore, the prevalence Of polycystic ovar*y syndrome (PCOS) is driving the growth of the iron deficiency injectables market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=12907&type=smp

Prominent Trend - Companies Introduce Innovative Iron Deficiency Therapies Like Injectafer To Expand Market Presence

Major companies operating in the iron deficiency injectables market are developing new therapies, such as INJECTAFER, to sustain their position in the market. For instance, in June 2023, Daiichi Sankyo Company, a US-based healthcare company and American Regent Inc., a US-based injectables manufacturer, launched INJECTAFER (ferric carboxymaltose injection) for iron deficiency, which the Food And Drug Administration, a US-based government agency, approved. This is the first and only intravenous iron replacement therapy for adult patients with chronic and progressive heart failure to receive FDA approval. More than 40 clinical trials involving more than 8,800 participants from different countries were examined with INJECTAFER. This latest approval builds on INJECTAFER's successful and demonstrated use in these patients, including adult and pediatric patients with iron-deficient anemia and heart failure.

Iron Deficiency Injectable Market Players
Major players in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Aetna Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, AstraZeneca PLC, GSK PLC, Fresenius Medical Care, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, Cipla Limited, Emcure Pharmaceuticals Ltd., AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH , Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc., Galen Medical Group.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the iron deficiency injectable market in 2023. The regions covered in iron deficiency injectable market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Iron Deficiency Injectable Market Report Structure
3. Iron Deficiency Injectable Market Trends And Strategies
4. Iron Deficiency Injectable Market - Macro Economic Scenario
5. Iron Deficiency Injectable Market Size And Growth
…..
27. Iron Deficiency Injectable Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.